Graphite Bio Announces Closing of Upsized Initial Public Offering & Full Exercise of Underwriters’ Option to Purchase Addit...
June 30 2021 - 5:15PM
Business Wire
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage,
next-generation gene editing company focused on therapies that
harness targeted gene integration to treat or cure serious
diseases, today announced the closing of its previously announced
initial public offering of 14,000,000 shares of its common stock at
a price to the public of $17.00 per share on June 29, 2021. In
addition, on June 29, 2021, the underwriters exercised in full
their option to purchase 2,100,000 additional shares of common
stock at the initial public offering price, less underwriting
discounts and commissions. The closing of the offering of the
additional shares is expected to occur on July 2, 2021.
The aggregate gross proceeds to Graphite Bio from the offering,
including the option exercise, will be $273.7 million, before
deducting the underwriting discounts and commissions and other
offering expenses payable by Graphite Bio. Graphite Bio’s common
stock is listed on the Nasdaq Global Market under the ticker symbol
“GRPH.”
Morgan Stanley, BofA Securities, Cowen and SVB Leerink are
acting as joint book-running managers for the offering.
Registration statements relating to these securities were filed
with the U.S. Securities and Exchange Commission (SEC) and became
effective on June 24, 2021. Copies of the registration statements
can be accessed through the SEC’s website at www.sec.gov. The
offering is being made only by means of a written prospectus,
forming a part of the effective registration statements. A copy of
the final prospectus relating to the initial public offering may be
obtained from: Morgan Stanley, Attention: Prospectus Department,
180 Varick Street, 2nd Floor, New York, NY 10014, or by email at
prospectus@morganstanley.com; BofA Securities, Attention:
Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd
Floor, Charlotte, NC 28255-0001, or by email at
dg.prospectus_requests@bofa.com; Cowen and Company, LLC, c/o
Broadridge Financial Solutions, Attention: Prospectus Department,
1155 Long Island Avenue, Edgewood, NY, 11717, by telephone at (833)
297-2926, or by email at PostSaleManualRequests@broadridge.com; or
SVB Leerink LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, by telephone at (800)
808-7525, ext. 6105, or by email at syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
where such offer, solicitation or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or jurisdiction.
About Graphite Bio
Graphite Bio is a clinical-stage, next-generation gene editing
company harnessing high efficiency targeted gene integration to
develop a new class of therapies to potentially cure a wide range
of serious and life-threatening diseases. Graphite Bio is
pioneering a precision gene editing approach that could enable a
variety of applications to transform human health through its
potential to achieve one of medicine’s most elusive goals: to
precisely “find & replace” any gene in the genome. Graphite
Bio’s platform allows it to precisely correct mutations, replace
entire disease-causing genes with normal genes or insert new genes
into predetermined, safe locations. The company was co-founded by
academic pioneers in the fields of gene editing and gene therapy,
including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D.,
Ph.D.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. These
statements may be identified by words such as “aims,”
“anticipates,” “believes,” “could,” “estimates,” “expects,”
“forecasts,” “goal,” “intends,” “may,” “plans,” “possible,”
“potential,” “seeks,” “will,” and variations of these words or
similar expressions that are intended to identify forward-looking
statements. Any such statements in this press release that are not
statements of historical fact may be deemed to be forward-looking
statements.
Any forward-looking statements in this press release are based
on Graphite Bio’s current expectations, estimates and projections
only as of the date of this release and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements, including the completion and timing of
the closing of the offering of the additional shares and the
anticipated gross proceeds. These risks concerning Graphite Bio’s
programs and operations are described in additional detail in its
final prospectus for the initial public offering, which is on file
with the SEC. Graphite Bio explicitly disclaims any obligation to
update any forward-looking statements except to the extent required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210630005997/en/
Company Contact: Stephanie Yao VP, Communications and Investor
Relations 443-739-1423 syao@graphitebio.com
Investor Relations: Stephanie Ascher Stern IR, Inc. 212-362-1200
ir@graphitebio.com
Media Contact: Christy Curran Sam Brown, Inc. 615-414-8668
media@graphitebio.com
Graphite Bio (NASDAQ:GRPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Graphite Bio (NASDAQ:GRPH)
Historical Stock Chart
From Jul 2023 to Jul 2024